Boston Scientific Corp has announced the signing of a definitiveagreement to acquire RadioTherapeutics Corp, a privately-held company based in California, USA, which develops and manufactures proprietary radiofrequency-based therapeutic devices. It specializes in the field of interventional oncology for the ablation of various forms of soft tissue lesions.
Terms of the agreement, which is expected to close in early December, were not disclosed, and Boston noted that RTC will become a part of its Medi-tech division.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze